# Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM)

> clinical trial · VERIFIED · 2026-06-29

Status: COMPLETED · Sponsor: Immunomic Therapeutics, Inc. · Condition: Glioblastoma

- Company: Immunomic Therapeutics, Inc.
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT05698199

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.